NewsNewsDetails
Clear Street reduces the target price of ArriVent Biopharma from $47 to $22
Businessinsider
1h ago
Ai Focus
Clear Street has lowered the target price of ArriVent Biopharma (AVBP) from $47 to $22, while maintaining a buy rating. The institution stated that the third-phase FURVENT trial of Firmonertinib did not meet expectations, mainly due to the chemotherapy group performing better than anticipated; according to an independent central review by blind method, the 9.5-month median progression-free survival period was a key risk point of the trial.
Helpful
No.Help

Clear Street has lowered the target price of ArriVent Biopharma ( AVBP ) from $47 to $22, while maintaining a buy rating for the stock.

In a research report sent to investors, the institution stated that the Phase III FURVENT trial of Firmonertinib did not meet expectations, mainly due to the chemotherapy group performing better than anticipated; according to the blinded independent central review, the median progression-free survival was 9.5 months. However, the PFS in the chemotherapy group varied across different studies, which is a key risk of this trial.

The institution added that the 11-month PFS of Firmonertinib was generally in line with its expectations for 10 months.

This article was originally published on TheFly — a real-time, market-influencing financial news source. Try it out >>

View more AVBP stocks with the best performance today >>

Read more about AVBP:

Disclaimer and Disclosure Report Issues

ArriVent Biopharma price target lowered to $22 from $45 at Jones

ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss , Cutting Price Target to $22

ArriVent Biopharma price target lowered to $18 from $45 at Truist

ArriVent Biopharma price target lowered to $18 from $45 at Jefferies

Midday Fly By : Uber to acquire ezCater, Paramount completes Warner Bros. deal

ArriVent Biopharma News MORE

Tip
$0
Like
0
Save
0
Views 21
WalletJYS reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”，and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Robinhood Adds $25 Million in Bitcoin to the Company’s Balance Sheet
Robinhood Makes its first corporate-level purchase of Bitcoin, adding BTC worth $25 million to the balance sheet. The company's head of cryptography, Johann Kerbrat, stated that this is more of a demonstration of investment in Bitcoin and the broader crypto ecosystem, rather than the initiation of a large-scale Bitcoin treasury strategy.
Coinpedia
·2026-10-07 19:45:13
7
Bitcoin Current Price on October 7th
At 7:15 a.m. Beijing time today, the price of Bitcoin was $83,759, down $2,522.11 from yesterday morning and about $37,630 lower than the same period last year. The article also introduces the basic concepts of Bitcoin, its price history, influencing factors, as well as common investment methods.
Fortune
·2026-10-07 19:45:09
8
OpenAI Executive Says How the Military's Use of AI "Keeps Me Waking at Night"
OpenAI, who is responsible for human rights and responsible deployment, stated that she is concerned about how the military might use AI for target identification and autonomous weapons. She said that OpenAI contacted her after signing a contract with the US military, and she is also working to ensure that the model responds appropriately to international rules such as the Geneva Conventions.
Fortune
·2026-10-07 19:45:07
8
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
Centene's subsidiary, Ambetter Health Solutions, announces a partnership with Marathon Health to provide eligible members in certain counties of Indiana and Missouri with $0 primary medical consultations, laboratory services, and virtual medical services starting from 2027.
PR Newswire
·2026-10-07 19:45:06
9
Top analyst Daniel Ives says SpaceX stock is "bigger than it looks"
SpaceX's stock price fell about 2% after the market closed on Tuesday, following reports that the company was seeking $40 billion in financing to purchase NVIDIA chips. Analyst Daniel Ives gave it a 'outperform the market' rating and a target price of $225, believing that SpaceX's rocket business, Starlink, and AI's services can complement each other.
Businessinsider
·2026-10-07 19:35:21
7
View More
Latest from Author
Refresh
arrow
TSA The new security scanner has a smaller opening, so some luggage may not be able to pass through, but most can still be accommodated.
TSA The new security scanner has a smaller opening, so some luggage may not be able to pass through, but most can still be accommodated.
09-26 23:29   279peopleViews
Micron Technology's stock price fluctuated before its Q4 financial report on September 30; institutions are optimistic about the demand for AI and the increase in storage chip prices.
Micron Technology's stock price fluctuated before its Q4 financial report on September 30; institutions are optimistic about the demand for AI and the increase in storage chip prices.
09-26 21:59   260peopleViews
OpenAI Reveals that AI Proxy Once Accessed Public Data from SEC
OpenAI Reveals that AI Proxy Once Accessed Public Data from SEC
09-26 09:45   296peopleViews
Recommended